3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
107
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Leukemia
23
Lymphoma
20
Recurrence
16
Burkitt Lymphoma
16
Lymphoma, Mantle-Cell
13
Neoplasms, Plasma Cell
11
Lymphoma, Non-Hodgkin
11
Waldenstrom Macroglobulinemia
9
Lymphoma, Follicular
9
Immunoglobulin Light-chain Amyloidosis
9
Hodgkin Disease
9
Breast Neoplasms
9
Vomiting
8
Neoplasms
8
Nausea
8
Lymphoma, B-Cell, Marginal Zone
8
Lymphoma, Large B-Cell, Diffuse
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma, T-Cell, Cutaneous
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Amyloidosis
6
Leukemia, Myeloid, Acute
5
Smoldering Multiple Myeloma
4
Sezary Syndrome
4
Mycosis Fungoides
4
Lymphoma, Large-Cell, Immunoblastic
4
Lung Neoplasms
4
Blast Crisis
4
Interventions
Dexamethasone
5
Magnetic Resonance Spectroscopy
4
Cyclophosphamide
4
Blood Specimen Collection
4
Surveys and Questionnaires
3
Prednisone
3
Melphalan
3
Lenalidomide
3
Biopsy, Fine-Needle
3
fluciclovine F-18
2
carfilzomib
2
Positron-Emission Tomography
2
Mammography
2
Injections
2
Immunohistochemistry
2
Gemcitabine
2
Cytarabine
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
weifuchun
1
vistusertib
1
venetoclax
1
technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid)
1
ricolinostat
1
pomalidomide
1
phosphoribosylformylglycinamidine synthetase
1
pembrolizumab
1
ofatumumab
1
obinutuzumab
1
lortalamine
1
irinotecan sucrosofate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Disease
×
Calcium Dobesilate
×
Clear all
NCT01857115
2024-11-13
wCCyd
European Myeloma Network B.V.
Phase 1/2
Completed
63 enrolled